Related references
Note: Only part of the references are listed.Over-accumulation of nuclear IGF-1 receptor in tumor cells requires elevated expression of the receptor and the SUMO-conjugating enzyme Ubc9
Hua Deng et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2011)
CD133 suppresses neuroblastoma cell differentiation via signal pathway modification
H. Takenobu et al.
ONCOGENE (2011)
CD133 expression in chemo-resistant Ewing sarcoma cells
Xiaohua Jiang et al.
BMC CANCER (2010)
Type 1 Insulin-like Growth Factor Receptor Translocates to the Nucleus of Human Tumor Cells
Tamara Aleksic et al.
CANCER RESEARCH (2010)
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sreenath V. Sharma et al.
CELL (2010)
CD133 expression is a potential prognostic indicator in intrahepatic cholangiocarcinoma
Mitsuo Shimada et al.
JOURNAL OF GASTROENTEROLOGY (2010)
SUMOylation Mediates the Nuclear Translocation and Signaling of the IGF-1 Receptor
Bita Sehat et al.
SCIENCE SIGNALING (2010)
Insulin-Like Growth Factor-1 Receptor Inhibition Induces a Resistance Mechanism via the Epidermal Growth Factor Receptor/HER3/AKT Signaling Pathway: Rational Basis for Cotargeting Insulin-Like Growth Factor-1 Receptor and Epidermal Growth Factor Receptor in Hepatocellular Carcinoma
Christele Desbois-Mouthon et al.
CLINICAL CANCER RESEARCH (2009)
Insulin, the Insulin-Like Growth Factor Axis, and Mortality in Patients With Nonmetastatic Colorectal Cancer
Brian M. Wolpin et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Resistance mechanisms to cancer chemotherapy
Kelly Marie Redmond et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2008)
CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway
S. Ma et al.
ONCOGENE (2008)
Insulin-like growth factor binding proteins IGFBP3, IGFBP4, and IGFBP5 predict endocrine responsiveness in patients with ovarian cancer
Graeme Walker et al.
CLINICAL CANCER RESEARCH (2007)
The insulin-like growth factor 1 receptor in cancer: Old focus, new future
Hermien Hartog et al.
EUROPEAN JOURNAL OF CANCER (2007)
Blockade of IGF-1 receptor tyrosine kinase has antlineoplastic effects in hepatocellular carcinoma cells
M Höpfner et al.
BIOCHEMICAL PHARMACOLOGY (2006)
The developing role of receptors and adaptors
C Massie et al.
NATURE REVIEWS CANCER (2006)
Management of hepatoceullular carcinoma
J Bruix et al.
HEPATOLOGY (2005)
Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma
HB El-Serag et al.
GASTROENTEROLOGY (2004)
Obesity and hepatocellular carcinoma
SH Caldwell et al.
GASTROENTEROLOGY (2004)
Primary liver cancer:: Worldwide incidence and trends
FX Bosch et al.
GASTROENTEROLOGY (2004)
IGFBP-3, a marker of cellular senescence, is overexpressed in human papillomavirus-immortalized cervical cells and enhances IGF-1-Induced mitogenesis
AC Baege et al.
JOURNAL OF VIROLOGY (2004)
The igf-1 receptor in cancer biology
R Baserga et al.
INTERNATIONAL JOURNAL OF CANCER (2003)
Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults
EE Calle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Nuclear localization of EGF receptor and its potential new role as a transcription factor
SY Lin et al.
NATURE CELL BIOLOGY (2001)
IGF-I receptor signalling in transformation and differentiation
B Valentinis et al.
JOURNAL OF CLINICAL PATHOLOGY-MOLECULAR PATHOLOGY (2001)
Estimating future hepatitis C morbidity, mortality, and costs in the United States
JB Wong et al.
AMERICAN JOURNAL OF PUBLIC HEALTH (2000)
Share Paper
